Adaptive Biotechnologies signed pharma deals with Biogen Idec for the study of the immune repertoire and the search for immunological biomarkers in difficult to treat autoimmune diseases.
Under the pharma deals collaboration, Adaptive's proprietary immune profiling assay, immunoSEQ, will be used to characterize the immune repertoire of patient samples with autoimmune disorders with high unmet medical needs.
The immunoSEQ assay uses high throughput next-generation sequencing to characterize the repertoire of T and B cell receptors, which can be very useful to monitor the immune status of patients with autoimmune diseases and to assess the impact of treatments that impact or alter the immune system and will be useful for the current pharma deals.
Adaptive Biotechnologies is pioneering the field of genomic immunology.
The company's core competency is developing next generation sequencing assays that characterize the adaptive immune system, serving as a platform technology to the research and clinical communities as well as the biopharmaceutical industry and this will be utilised in the pharma deals.
Report: Partnering Deals and Alliances with Biogen Idec
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity